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Background: Medical therapy for multiple sclerosis (MS) is expensive. Quantifying the burden 
of MS is fundamental for health-care planning and the allocation of resources for the manage-
ment of MS. This study provides current national estimates of prevalence, incidence, mortality, 
and costs of MS in Switzerland using claims data between 2011 and 2015.
Methods: We analyzed health insurance claims of adult persons enrolled with a large health insur-
ance group covering about 13% of the Swiss population between 2011 and 2015. The identification 
of patients with MS was based on prescription data of MS-specific medication using the Anatomical 
Therapeutic Chemical Classification system as proxy for clinical diagnosis. We estimated prevalence, 
mortality, and costs of basic health insurance between 2011 and 2015. Furthermore, incidence of 
MS was calculated for 2015. All results were weighted with census data to achieve an extrapolation 
to the Swiss general population level. Cost of illness was estimated as direct medical cost from the 
perspective of a Swiss health insurance using multivariate linear regression analysis.
Results: Of the 943,639 subjects in the year 2015, 1,606 were identified as MS patients resulting 
in a prevalence of 190 per 100,000 (95% CI: 180−190 per 100,000). Incidence was 16 per 100,000 
(95% CI: 13−19 per 100,000). According to regression analysis, the total cost of illness for basic 
mandatory health insurance was 26,710 Swiss Francs (CHF) (95% CI: 26,100–27,300) per person per 
year with the cost of medication being almost identical 26,960 CHF (95% CI: 26,170–27,800).
Conclusions: MS affects 10,000–15,000 persons in Switzerland, and the prevalence has 
increased over the last 22 years. These persons have high need and demand for health care. 
High costs are primarily due to expenses for medication. Given the imbalance of MS medication 
therapy from the perspective of basic health insurance on the disposable resources, it is crucial 
to increase transparency related to the volume, type, and allocation of expenses.
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Background
Multiple sclerosis (MS) is a chronic, so far incurable neurodegenerative disease often 
with an unpredictable course.1 MS is associated with a broad spectrum of symptoms such 
as loss of bladder and bowel control, cognitive disorders, or psychological and psychi-
atric problems.2 MS causes both utilization of health-care services and a decrease of labor 
capacity.3–5 It is estimated that more than 2 million persons worldwide suffer from MS 
which is one of the most common causes of neurological disability in young adults.6
Costs for care of patients with MS is highly correlated with disease severity.7,8 Costs 
of drugs have been shown to be main cost drivers in MS patients.9 New and promising 
therapies are being developed which, in turn, are associated with high costs in addi-
tion to existing therapies.10 Although there is still uncertainty related to comparative 
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effectiveness of the different MS drugs,11,12 cost of fingolimod, 
for example, an immunosuppressive agent for the therapy of 
relapsing remitting MS increased in Switzerland by 750% 
from 2011 to 2014 indicating high dynamics in the use of MS 
medication.13 Measures of prevalence and incidence help to 
monitor disease burden in the population and are a basis for 
health-care planning and the allocation of resources for the 
management of MS, especially given the high costs associated 
with these new therapies.14
Previous surveys evaluated prevalence of MS in 
Switzerland. However, due to the methodological limitations 
of surveys, these results may be subject to sample selection 
bias, nonresponse, and inaccurate recall. In part, these data are 
quite outdated.15,16 In addition, to our knowledge, there are no 
incidence data for MS in Switzerland. With respect to costs 
of MS, one previous study published in 2006 was done in the 
Swiss health-care system.7 However, the expensive therapeutic 
innovations that have been established in recent years are likely 
to have impacted costs of MS in Switzerland. In the absence of 
other reliable data sources on MS, the analysis of health-care 
claims data is a useful approach to display the epidemiology 
and costs of MS. Claims data are reliable, cover a large popula-
tion, and are widely used in epidemiological research.17
The aim of the present study is to assess actual prevalence, 
incidence, and costs of MS in Switzerland using claims data 
from one of the largest health insurances in Switzerland 
covering about 13% of the Swiss population (ca. 1.2 million 
persons with basic mandatory health insurance).
Methods
study population and context of the 
study
Health insurance is mandatory in Switzerland, and the basic 
benefit package is the same in the entire country. The pres-
ent study included health insurance claims from ~1.2 million 
adult persons aged 19 years or older residing in Switzerland 
who were enrolled with the Helsana Group. Data for the years 
2011–2015 were used. All Swiss residents need to contract 
basic health insurance on a private market of health insurance, 
which is regulated by federal bodies. In order to protect those 
with poor health, health insurers are obliged to offer basic 
insurance to everyone and to charge the same premium to 
every individual irrespective of age or health status. Basic 
health insurance includes all outpatient or hospital medical 
treatment deemed appropriate, medically effective, and cost-
effective. Supplementary hospital insurance in Switzerland 
covers further comfort of a semiprivate or private ward or 
treatment in another canton for personal reasons.18 The insured 
person pays a share of the cost of health care in the form of an 
annual deductible cost (called a “franchise”) ranging from 300 
to a maximum of 2,500 CHF as selected by the insured person 
and a charge of 10% of the costs up to 700 CHF per year. 
Currently, there are 57 insurance companies providing basic 
health coverage in Switzerland, and they offer a range of dif-
ferent premiums and types of health plans from which Swiss 
residents are free to choose.18,19 Managed care models are 
alternative insurance models for mandatory health insurance 
under which the insured persons agree to always first consult 
a specific type of health-care provider (ie, a group practice, a 
fixed family doctor, or a telemedicine center).18,20
Identification of patients with MS
Health insurance claims data in Switzerland do not include 
diagnoses from the ambulatory sector. We, therefore, used 
the WHO Anatomical Therapeutic Chemical (ATC) clas-
sification system for drugs to identify patients with MS.21 
Long-term care (including prescription of medication therapy 
of MS) is done predominantly in the outpatient sector. Thus, 
this identification process guarantees approximately full 
capturing of all MS patients receiving drug treatment.
One or more treatments with one of the following drugs 
were used for identification of MS patients (Table 1).
Table 1 List of drugs used for identification of MS patients
ATC code Brand name Active agent Substance class
l01Xc02 Mabthera rituximab Monoclonal antibody
l03aB07 avonex interferon beta-1a interferon
l03aB07 rebif interferon beta-1a interferon
l03aB08 Betaferon interferon beta-1b interferon
l03aB13 Plegridy Peginterferon beta-1a interferon
l03aX13 copaxone glatiramer acetate Other immunostimulants
l04aa23 Tysabri Natalizumab selective immunosuppressants
l04aa27 gilenya Fingolimod selective immunosuppressants
l04aa31 aubagio Teriflunomide selective immunosuppressants
l04aa34 lemtrada alemtuzumab selective immunosuppressants
N07XX09 Tecfidera Dimethyl fumarate Other nervous system drugs
Abbreviations: aTc, anatomical Therapeutic chemical; Ms, multiple sclerosis.
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The use of rituximab is off-label for MS, and alemtuzumab 
was off-label until January 2015. According to the Swiss 
Federal Health Insurance Ordinance, off-label use has to be 
approved by a medical examiner of basic mandatory health 
insurance. So, for these two drugs, indication of therapy is 
documented in the health insurance claims. We included 
only those cases in which rituximab and alemtuzumab were 
unambiguously used for the treatment of MS.
sociodemographic variables, morbidity, 
and mortality
Available population characteristics included gender, age, 
language, area, and type of insurance coverage (managed 
care model, deductible class, etc.), and the presence of 
chronic condition using pharmaceutical cost groups (PCG). 
If medical diagnosis information is missing in the available 
data set, PCGs are established individual markers for selected 
chronic conditions.22 All-cause mortality of the study sample 
was recorded.
cost data
Direct medical costs were derived from the perspective of 
Swiss basic mandatory health insurance. The database also 
contained information on all reimbursed invoices covering 
all settings of outpatient and inpatient care and nursing care. 
Since the recorded insurance claims cover almost all health-
care invoices, the data achieve a high degree of complete-
ness. Annual total direct medical costs were obtained from 
providers’ claims and defined as the total payments made by 
the mandatory health insurance for outpatient and inpatient 
services per patient per year. Costs from the outpatient set-
ting comprised payments for office-based physician visits, 
hospital outpatient visits, paramedical visits, medications, 
laboratory tests, and medical devices. Inpatient costs covered 
payments for hospital treatments, rehabilitation, nursing 
home, and emergency transport services. Inpatient costs 
also cover the cost of medications, laboratory and medical 
services during the inpatient episode. Costs are given in 
CHF and are not adjusted for inflation during the observa-
tion period.
statistical analysis
We calculated annual MS prevalence for 2011 to 2015 by 
dividing the number of patients with MS by all insured per-
sons in the sample in the same year. In order to determine 
the incidence of MS in 2015, the number of newly identified 
cases with MS divided by the study population which is free 
of MS medication at the beginning of the year was calculated. 
We classified patients as incident cases if they were identi-
fied as MS patients in 2015 and had a minimum MS-free 
period of 2 years in the previous years. In order to achieve 
representative estimates for Switzerland, all measures of 
prevalence, incidence, cost, and mortality were projected 
to the total population of Switzerland. This projection was 
done by increasing the number of persons and cost by the 
market share of Helsana for every group defined by age 
group, gender, and canton of residence. Cost of illness for MS 
was estimated using multivariate regression analysis. Due 
to the data being highly skewed to the right, a generalized 
linear model (glm) was chosen with log-link and gamma-
type variance structure. Only patients with positive medical 
costs were included in the model. As covariates, age group, 
sex, indicator for deceased, deductible class, managed care 
plan, accident coverage, supplementary inpatient insurance, 
and canton of residence were used. The model was fitted to 
the 2015 data. To measure the cost of illness, the marginal 
effects for each MS patient were calculated and averaged. 
First, the mean expected values for the MS patients were 
calculated and then the mean expected values for the MS 
patients treating them as non-MS patients were subtracted. 
This procedure was performed by bootstrapping for 1,000 
samples of 1,000 individuals each from the population of 
the MS patients selected randomly with replacement. These 
marginal effects were calculated for the total costs and the 
total medication costs. The results indicated are the 2.5% 
percentile, the mean, and the 97.5% percentile of these 1,000 
cost differences. All statistical analyses were performed using 
R, version 3.2.0.
ethical approval
The analysis complied with the Swiss Federal Law on data 
protection. All data were anonymized and de-identified prior 
to the performed analysis. According to the national ethical 
and legal regulation, an ethical approval was not needed 
because the data were retrospective, preexisting, and de-
identified. Since data was anonymized, no consent of patients 
was required. Basic health insurance data in Switzerland is 
not publicly available.
Results
Our study population included about 940,000 subjects in 
each of the five investigated years comprising about 1,410 
MS patients per year (detailed numbers of the study samples 
are shown in Table 2).
Characteristics of patients with MS in comparison with 
persons without MS are shown in Table 3. MS patients differed 
in all investigated socioeconomic variables. They were about 
6 years younger (45.5 versus 51.8 years), more frequently 
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female (72.9% versus 52.5%), had more frequently a low 
annual deductible (94.6% versus 67.9%), were less frequently 
enrolled in a managed care health plan (48.4% versus 
59.1%), had less frequently accident coverage (50.3% versus 
53.1%) and supplementary inpatient insurance (15.3% ver-
sus 18.2%). MS patients also differed in terms of clinical 
characteristics: MS patients suffered from more chronic 
conditions (as measured using PCGs) (2 versus 1.3) and 
used more different medications (10.8 versus 6.7). However, 
MS patients were less likely to die during the investigated 
insurance years (0.3% versus 1.3%). The presence of a 
severe disease also reflects in higher health service utiliza-
tion in MS patients as compared to non-MS persons. This is 
most obvious in medication cost to basic health insurance: 
MS patients had about 20-fold higher total medication costs 
(21,023 versus 1,048 CHF) and 8-fold higher outpatient 
Table 2 sample size per year: persons with basic mandatory 
health insurance enrolled with the helsana group
Year Sample (N) MS patients (N)
2011 925,003 1,262
2012 944,621 1,354
2013 947,723 1,338
2014 940,086 1,494
2015 943,639 1,606
Abbreviation: Ms, multiple sclerosis.
Table 3 socioeconomic, clinical, and health utilization characteristics of the study population for persons with and without Ms 
(year 2015)
Characteristic Measure MS patients no MS Total p-value
age (years) n (%) 1,606 (0.2) 942,033 (99.8) 943,639 (100)
mean (median) 45.5 (46) 51.8 (51) 51.8 (51) ,0.001
age group: 19–25 n (%) 72 (4.5) 89,567 (9.5) 89,639 (9.5) ,0.001
26–30 n (%) 117 ( 7.3) 64,042 (6.8) 64,159 (6.8)
31–35 n (%) 197 (12.3) 74,756 (7.9) 74,953 (7.9)
36–40 n (%) 203 (12.6) 76,922 (8.2) 77,125 (8.2)
41–45 n (%) 213 (13.3) 76,807 (8.2) 77,020 (8.2)
46–50 n (%) 263 (16.4) 81,874 (8.7) 82,137 (8.7)
51–55 n (%) 208 (13.0) 80,971 (8.6) 81,179 (8.6)
56–60 n (%) 136 (8.5) 73,440 (7.8) 73,576 (7.8)
61–65 n (%) 99 (6.2) 68,397 (7.3) 68,496 (7.3)
66–70 n (%) 57 (3.5) 67,796 (7.2) 67,853 (7.2)
71–75 n (%) 25 (1.6) 60,260 (6.4) 60,285 (6.4)
76–80 n (%) 14 (0.9) 48,479 (5.1) 48,493 (5.1)
81–85 n (%) 1 (0.1) 39,501 (4.2) 39,502 (4.2)
86–90 n (%) 1 (0.1) 25,520 (2.7) 25,521 (2.7)
91 –… n (%) 0 (0.0) 13,701 (1.5) 13,701 (1.5)
Female n (%) 1,170 (72.9) 494,508 (52.5) 495,678 (52.5) ,0.001
Deductible (chF) Mean (median) 401 (300) 879 (300) 878 (300) ,0.001
low deductiblea n (%) 1,519 (94.6) 639,544 (67.9) 641,063 (67.9) ,0.001 
Managed care plan n (%) 777 (48.4) 556,543 (59.1) 557,320 (59.1) ,0.001
accident coverage n (%) 808 (50.3) 499,799 (53.1) 500,607 (53.1) 0.030
suppl inpatient insurance coverage “yes” n (%) 245 (15.3) 171,417 (18.2) 171,662 (18.2) 0.003
No of Pcgs Mean (median) 2 (2) 1.3 (1) 1.3 (1) ,0.001
No of different aTc Mean (median) 10.8 (9) 6.7 (4) 6.7 (4) ,0.001 
Deceased n (%) 5 (0.3) 12,265 (1.3) 12,270 (1.3) ,0.001
cost of Ms medication Mean (median) 19,609 (20,326) 0 (0) 33 (0) ,0.001
cost of total medication Mean (median) 21,023 (20,930) 1,048 (205) 1,082 (206) ,0.001
Outpatient cost Mean (median) 27,459 (26,509) 3,452 (1,372) 3,493 (1,378) ,0.001
inpatient cost Mean (median) 1,486 (0) 1,513 (0) 1,513 (0) 0.050
Total cost Mean (median) 28,945 (27,269) 4,965 (1,466) 5,006 (1,472) ,0.001
No of gP visits Mean (median) 5.4 (4) 3.7 (2) 3.7 (2) ,0.001
No of specialist visits Mean (median) 7.6 (5) 3.4 (1) 3.4 (1) ,0.001
No of hospital outpatient visits Mean (median) 6.8 (3) 2.3 (0) 2.3 (0) ,0.001
inpatient length of stay Mean (median) 1.4 (0) 1.6 (0) 1.6 (0) 0.332
No of hospitalization episodes Mean (median) 0.2 (0) 0.2 (0) 0.2 (0) 0.416
Note: a#500 chF per year.
Abbreviations: chF, swiss Francs; gP, general practitioner; Ms, multiple sclerosis; Pcgs, pharmaceutical cost groups; aTc, anatomical Therapeutic chemical; suppl, 
supplementary.
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costs as compared to non-MS persons (27,459 versus 3,452 
CHF). Consistently, the number of visits with general prac-
titioners (GPs; 5.4 versus 3.7), specialists (7.6 versus 3.4), 
and outpatient hospital visits (6.8 versus 2.3) was higher in 
MS patients. In contrast, these differences were not present 
for the inpatient sector: inpatient cost, inpatient length of 
stay, and number of inpatient stays did not statistically sig-
nificantly differ. The pattern of differences was similar for 
the years 2011–2015.
Table 4 shows the overall prevalence of MS of 150 per 
100,000 (estimate for 2011) to 190 per 100,000 (estimate 
for 2015) which translates to 10,000 (estimate for 2011) to 
12,600 individuals with MS in Switzerland (estimate for 
2015). Our results show a slight but continuous increase in 
prevalence of MS from 2011 to 2015. The incidence of MS 
was 16 per 100,000 (95% CI: 13–19 per 100,000) which 
means that 1,100 individuals (95% CI: 910–1,280) receive 
a diagnosis of MS per year in Switzerland (Table 5).
The crude mortality rate of the MS patients was very low 
and ranged from 0% (estimate for 2012 when no deceased 
MS patient was observed) to 0.248% (estimate for 2014) 
(Table 6). The corresponding confidence intervals range from 
0% to 0.484%. The corresponding crude rates for non-MS 
patients, extrapolated to the general population of Switzerland, 
were about four times higher than those for MS patients.
Extrapolated costs for MS medication in Switzerland 
oscillated around 19,000 CHF per year (Table 7). In conse-
quence, mean overall costs for medication is about 24 times 
higher in MS patients as compared to non-MS persons 
with a difference of about 21,000 CHF per year (Table 8). 
Consistently, there were substantial differences in total 
health-care costs between MS patients and non-MS persons 
with total health-care costs being about seven times higher in 
MS patients. The difference ranged between 22,700 (estimate 
for 2011) and 26,000 (estimate for 2012) without a trend for 
increase over the investigated time period (Table 9).
The estimates of direct cost for MS derived from multi-
variate regression analysis for the year 2015 were 26,960 
CHF (95% CI: 26,170–27,800) per person per year for cost 
of medication and 26,710 CHF (95% CI: 26,100–27,300) 
for total health-care costs when controlling for various 
confounders. CIs of both estimates overlapped indicating 
that they did not statistically significantly differ.
Discussion
This study provides current estimates of prevalence, inci-
dence, mortality, and cost of MS in Switzerland. MS is a 
rare disease affecting 10,000–15,000 persons in Switzerland. 
It reveals that medication therapy for MS is the major part of 
Table 4 Prevalence of MS (2011–2015), stratified by age group and sex extrapolated to the total population of Switzerland
Sex Age 
group
2011 2012 2013 2014 2015
Prevalence 
per 100,000
95% CI Prevalence 
per 100,000
95% CI Prevalence 
per 100,000
95% CI Prevalence 
per 100,000
95% CI Prevalence 
per 100,000
95% CI
Male 19–40 110 90–120 100 80–120 90 80–110 100 80–120 100 80–120
Female 19–40 220 200–250 230 210–260 240 210–260 260 240–290 280 250–300
Male 41–65 120 100–130 120 100–140 120 110–140 140 120–160 140 120–160
Female 41–65 290 270–320 310 280–330 300 270–330 330 310–360 370 340–400
Male $66 20 10–30 20 10–20 20 10–20 20 10–30 20 10–30
Female $66 40 30–50 40 30–50 40 30–50 60 40–70 60 40–70
Total 150 140–160 160 150–170 160 150–170 180 170–180 190 180–190
Abbreviation: Ms, multiple sclerosis.
Table 5 Incidence of MS (2015), stratified by age group and sex, 
extrapolated to the total population of switzerland
Sex Age  
group
2015
Incidence  
per 100,000
95% CI
Male 19–40 10 5–14
Female 19–40 38 27–48
Male 41–65 8 4–11
Female 41–65 28 20–35
Male $66 1 0–2
Female $66 1 0–1
Total 16 13–19
Abbreviation: Ms, multiple sclerosis.
Table 6 Mortality of persons with and without Ms in % (2011–
2015), extrapolated to the total population of switzerland
Year Non-MS 95% CI MS 95% CI
2011 1.014 0.996–1.032 0.230 0.016–0.443
2012 1.018 1.000–1.036 0.000 0.000–0.000
2013 1.015 0.998–1.033 0.109 0.000–0.250
2014 0.971 0.954–0.989 0.248 0.012–0.484
2015 1.023 1.006–1.041 0.245 0.045–0.445
Abbreviation: Ms, multiple sclerosis.
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Table 8 Mean overall costs of basic health insurance for medication and difference between persons with and without Ms in swiss 
Francs (2011–2015), extrapolated to the total population of switzerland
Year Non-MS 95% CI MS 95% CI Difference 95% CI
2011 920 910–930 23,000 22,300–23,700 22,100 21,400–22,800
2012 950 940–960 24,200 23,700–24,700 23,200 22,700–23,800
2013 940 930–950 21,900 21,500–22,400 21,000 20,500–21,400
2014 950 940–960 21,100 20,700–21,500 20,100 19,700–20,500
2015 980 980–990 21,100 20,700–21,500 20,100 19,700–20,500
Abbreviation: Ms, multiple sclerosis.
health-care costs in MS patients, and cost of illness for basic 
mandatory health insurance can almost entirely be explained 
by cost of MS medication.
Kingwell et al14 systematically reviewed the incidence 
and prevalence of MS in Europe. They found a large 
variation in prevalence ranging from 15 cases/100,00023,24 to 
230 cases/100,000.25 They criticized that the identified studies 
lacked standardization related to case definition, and they 
concluded that further national-level studies were needed, 
especially when considering that prevalence is closely related 
to geographic, ethnic, and genetic factors.6 However, the 
prevalence estimate of about 160 cases/100,000 identified 
in the present study is plausible and ranks in the midfield of 
the prevalence estimates extracted from 123 studies. Another 
estimate of currently 12,500 persons with MS living in Swit-
zerland is perfectly in line with our results.15
The preceding prevalence study by Beer and Kesselring 
found a prevalence of 110 MS cases/100,000 inhabitants in 
Switzerland in 1994.16 The MS Barometer, a report of compar-
ative MS data provided by European national MS societies 
organized as “European Multiple Sclerosis Platform” 
reports for Switzerland a prevalence of MS of 105/100,000 
for the year 2009 and of 148/100,000 for the year 2011.26 
Our study resulted in an estimate of 150/100,000 for 2011 and 
of 190/100,000 for 2015. Even if there is some imprecision 
related to these estimates, there is a clear trend indicating an 
increase in MS prevalence in Switzerland. This conclusion 
is supported by the fact that the prevalence estimates are 
derived from different data sources which increases trust in 
the generalizability of the results. However, the question is 
whether this increase in prevalence is real.27 For example, the 
increased availability of magnetic resonance imaging and, 
consequently, improved diagnosis of MS may explain an 
apparent increase in prevalence.28 Specifically, the time delay 
between onset and diagnosis of MS has probably declined, and 
the diagnostic awareness among physicians and patients has 
increased.29 Thus, the rise in prevalence is – at least in part – 
a consequence of the underestimated prevalence reported 
previously. Otherwise, the growth in prevalence may be due 
to an improved probability of survival.30,31 In addition, many 
potential etiological factors such as infection, immuniza-
tions, physical and emotional stressors, climate, diet, and 
occupational exposures have been suspected to trigger the 
autoimmune disease among susceptible people.32–35
However, none of these hypotheses are fully validated, 
and it is unclear, whether these factors have changed in the 
past years in Switzerland. Certainly, this increase of MS has 
been observed internationally.14,36 Future epidemiological 
studies are needed to search for potentially preventable 
causes of MS.
Recently, the Swiss MS Cohort has been established – a 
prospective observational study including 872 MS patients 
from 7 large MS centers across Switzerland. This cohort 
study may help to investigate the mechanisms leading to 
disability and the long-term efficacy and safety of disease 
modifying drugs (DMDs) in MS.37 The cohort might also be 
helpful in identifying potential environmental risk factors 
relevant in Switzerland.
A recent survey supported by the European Platform of 
MS Societies (EMSP) investigated burden and costs of MS in 
Switzerland.5 In this study, mean annual costs varied between 
29,600 CHF for low disability scores, 66,800 CHF for moder-
ate, and 110,800 CHF for high disability scores. However, 
these cost estimates also included various costs not covered 
by basic health insurance such as early retirement, work 
absence, informal care, or community services. Health-care 
costs varied between 19,421 (±15,616) and 34,910 (±53,040) 
CHF, so that the estimates derived from the present study are 
Table 7 Mean annual costs of Ms medication of basic health 
insurance (2011–2015) in swiss Francs per person per year, 
extrapolated to the total population of switzerland
Year Mean costs 95% CI
2011 20,400 19,900–20,900
2012 19,700 19,200–20,100
2013 19,800 19,300–20,200
2014 18,500 18,100–18,900
2015 19,600 19,300–20,000
Abbreviation: Ms, multiple sclerosis.
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coherent. However, costs for medication in the EMSP study 
were somewhat lower (10,752–16,009 CHF). As the EMSP 
study was based on self-report, potential imprecision and 
recall bias may have contributed to the difference between 
those estimates and the results of the present study.
A recent systematic review collected 48 cost of illness 
studies in MS and found out that medications were the 
main cost drivers for MS patients with low disease severity, 
representing 29%–82% of all costs in this patient group. 
However, the main predictors of costs for groups with more 
advanced MS symptoms were production losses due to MS 
and informal care, accounting for 17%–67% of costs in 
those groups.9 Thus, there is a big difference in resource 
utilization at different stages of the disease. Disease modify-
ing therapies are most appropriate at low severity, and the 
goal of treatment is to prevent progression. When disease 
progresses, costs associated with MS drugs decrease, and 
the pattern of expenditure changes. The comparability of 
the cost of illness estimate of the present study with figures 
derived from other healthcare settings is very limited as 
data are based on different structures of the reimbursement 
system, the insurance coverage, and the organization of 
health services.
Current clinical practice guidelines recommend medica-
tion therapy based on severity levels of the disease. However, 
to date, there is a lack of good quality head-to-head compari-
sons between the new oral immunotherapies, new monoclo-
nal antibodies, and the established immunotherapies.38 Given 
the predominant role of medications for the use of resources 
in MS patients, the uncertainty related to comparative effec-
tiveness of MS medications is striking.11
Different limitations need to be considered when inter-
preting the results of this study. Firstly, our study was based 
on reimbursement data from mandatory health insurance, 
and we were not able to include clinical information or 
information related to indirect costs and costs for informal 
care. However, routine data from basic mandatory health 
insurance depicts real-life management as it includes all 
diagnostic, therapeutic, and rehabilitative measures that have 
been reimbursed. Secondly, in the absence of ambulatory 
diagnostic information in our data set, we identified MS 
cases based on MS-specific medication. However, it is very 
unlikely that patients agree to take MS medication which is 
associated with severe adverse events such as activation of 
other autoimmune disorders, leukopenia, or bradycardia when 
there are no clear diagnostic criteria or severe suffering.39,40 
Thirdly, we used data from a single health insurance, and 
results may differ across populations of different health 
insurances across Switzerland. However, we used data from 
one of the largest health insurances covering about 13% of 
the Swiss population from all parts of the country, and we 
extrapolated the results to the general population of Switzer-
land to account for differences in the market share different 
demographic subgroups. Fourthly, the present study adopts a 
purely unidimensional perspective as it focuses on the cost for 
basic mandatory health insurance. Other dimensions impact-
ing cost of illness such as sickness absence, early retirement 
due to MS, or informal care were not considered as they are 
not part of the mandatory benefits package in Switzerland 
and can thus not be captured by basic mandatory health 
insurance. In addition, comparisons were made between 
persons with MS medication, used as an identifier of disease, 
and the population without MS medication. Comorbidities 
present in both groups were not adjusted for. Nevertheless, 
our study confirms the prominent role of MS medication for 
costs caused by the care for persons with MS.
The present study has implications for future research. 
Good quality evidence and clinical guidelines are needed to 
define criteria related to the selection of the most appropri-
ate medication, required security checks such as regular 
blood cell counts or electrocardiogram, contraindications 
and practical guidance for change of treatment. Further evi-
dence related to direct comparisons between active agents 
is needed including the medium- and long-term benefit and 
safety of immunotherapies and the comparative safety of 
different agents.10 It is the interest of both affected patients 
and premium payers that the high costs caused by the use 
of MS medications is strictly effective, safe, and efficient. 
Table 9 Mean overall health-care costs of basic health insurance (per person per year) and difference between persons with and 
without Ms in swiss Francs (2011–2015), extrapolated to the total population of switzerland
Year Non-MS 95% CI MS 95% CI Difference 95% CI
2011 4,080 4,060–4,100 26,800 26,000–27,600 22,700 21,900–23,500
2012 4,240 4,220–4,260 30,300 29,500–31,000 26,000 25,300–26,800
2013 4,300 4,280–4,320 29,700 28,900–30,400 25,400 24,600–26,100
2014 4,440 4,410–4,460 28,700 28,000–29,400 24,300 23,600–24,900
2015 4,550 4,530–4,570 28,800 28,200–29,400 24,300 23,600–24,900
Abbreviation: Ms, multiple sclerosis.
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The basis of these principles is transparency related to the 
burden of disease both on the individual and on the popula-
tion level, and transparency related to costs and efficiency 
of care for MS.
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